Although the mechanism of the benefit of colchicine was not investigated in this trial, colchicine has been shown to acutely lower the local production of NLRP3 inflammasome-related cytokines, IL-1β, IL-18, and IL-6, in the coronary vascular bed of patients with CAD [168]. Here, IL6 is linked to coronary artery disorder.